Loading clinical trials...
Loading clinical trials...
A Phase 4, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Single-dose, Five-way Crossover Study Evaluating the Abuse Potential of Three Doses of NEURONTIN® Taken Orally in Healthy, Non-drug Dependent Participants With Sedative Drug Abuse Experience
Conditions
Interventions
gabapentin 600 mg
gabapentin 1200 mg
+3 more
Locations
1
United States
Pharmaceutical Research Associates, Inc.
Salt Lake City, Utah, United States
Start Date
March 29, 2021
Primary Completion Date
November 10, 2022
Completion Date
November 10, 2022
Last Updated
July 24, 2024
NCT05106153
NCT03200080
NCT01987739
Lead Sponsor
Viatris Specialty LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions